久久久久婷婷社区,不卡尤物AV在线

Axalta 2024 Financial Report Financial statements Axalta's 2024 sales in China reached 4.1 billion RMB, driven by strong demand in the automotive and new energy vehicle markets. The company experienced significant growth, marking a historical high for the region.
Nippon Paint 2024 Financial Report Financial statements Nippon Paint China achieved a 13% revenue growth in 2024, reaching 545.2 billion yen. Strong sales in automotive, industrial, and architectural coatings drove growth, despite challenges in the real estate sector. The company aims for further expansion in 2025.
Jotun's 2024 Financial Report Financial statements Jotun's revenue grew by 7.4% to $3.2 billion in 2024, with strong sales momentum across all segments. The company expects continued growth in 2025 despite economic uncertainties, focusing on profitability and cost control amid competitive market conditions.
RNAi Giant Alnylam Pharmaceuticals: $12 Billion in Sales! Financial statements Alnylam Pharmaceuticals reports $2.248 billion in 2024 revenue, driven by RNAi drug sales. The company continues to innovate in rare diseases, cardiovascular, and neurological treatments with a promising pipeline.
Behr's 2024 Financial Report Financial statements Masco's Behr paint business generated $2.505 billion in 2024, with PRO paint sales growing and DIY sales declining. Despite a 5% segment revenue drop, operating margins improved. Masco expects steady 2025 growth, focusing on efficiency, acquisitions, and capital returns.
Biogen's 2024 Financial Report Financial statements Biogen cuts four pipeline programs and secures a $1.8 billion deal with Royalty Pharma. Leqembi, its Alzheimer’s treatment, achieves $281M in global sales for 2024. Multiple sclerosis remains its top revenue driver amid a 2% overall revenue decline.
Gilead's 2024 Financial Report Financial statements Gilead's 2024 revenue reached $28.75B, up 6%. Biktarvy led with $13.4B in sales, while CAR-T therapies generated $1.97B. HIV, oncology, and liver disease segments saw strong growth. Veklury sales declined. 2025 product sales forecast: $28.2B-$28.6B.
BMS 2024 Annual Report Financial statements BMS reported a 7% increase in 2024 revenue to $48.3B, driven by strong growth from Eliquis and Camzyos. The company projects a decline in legacy product sales in 2025 but plans to save $2B in costs by 2027.
AstraZeneca 2024 Financial Report Financial statements AstraZeneca’s 2024 financial results show strong growth with total revenue of $54.07 billion, driven by key products like Tagrisso, Farxiga, and Enhertu. China’s market contributed $6.4 billion, and the company expects continued high growth in 2025.
Axalta's 2024 Financial Results Financial statements Axalta reports record 2024 sales of $5.3 billion, with a 45% increase in net profit. Strong performance in automotive and light vehicle coatings led to impressive growth, alongside robust transformation initiatives and favorable pricing.

< Pre 1...7 8 91011 12 13...15 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

国产91视频久久,亚洲综合色图在线观看,五月天操逼网,日韩色色AV,青青在线A片,亚洲最大色在线观看,欧美熟妇丝袜诱惑,青青操逼视频,日韩无码操出水